Gabay Avraham sold $90K of ORMP
Gabay Avraham (Chief Financial Officer) sold 20,000 shares of ORAMED PHARMACEUTICALS INC. (ORMP) at $4.51 on 2026-10-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The CFO's sale reduces his ownership but remains a small fraction of total shares; market reaction is expected to be muted.
Market read
A modest insider sale with limited price impact; primarily of interest to short‑term traders monitoring insider activity.
What to watch
Potential upcoming corporate actions or financing needs not disclosed in the filing.
Background
Form 4 disclosures are primary sources for insider transactions and are used to gauge insider sentiment.
Ticker impact
CFO Gabay Avraham sold 20,000 shares for $90,200 via a 10b5‑1 plan, reducing his stake to 861,076 shares.
likely slight downward pressure as the market prices the CFO's sale
Form 4 filing shows a direct sale by a senior officer; size is modest but could influence short‑term sentiment.
Market effects
Minimal impact on the biotech/pharma sector; typical insider sales are routine.
No broader regional effect.
Limited to Oramed shareholders.
Counterpoint
The sale could be a routine liquidity event and not indicative of negative fundamentals.
Key entities
- IndividualGabay Avraham
Chief Financial Officer of Oramed Pharmaceuticals
- CompanyOramed Pharmaceuticals Inc.
NASDAQ‑listed biotech firm (ORMP)